الفرق بين المراجعتين لصفحة: «ساكساغلبتين»
اذهب إلى التنقل
اذهب إلى البحث
(نقل النص للترجمة) |
(إخفاء النص الإنكليزي لترجمته لاحقاً بكود <!-- -->) |
||
| سطر 50: | سطر 50: | ||
| StdInChIKey = QGJUIPDUBHWZPV-SGTAVMJGSA-N | | StdInChIKey = QGJUIPDUBHWZPV-SGTAVMJGSA-N | ||
}} | }} | ||
الساكساغلبتين {{إنج|Saxagliptin}} ([[International Nonproprietary Name|rINN]]) سمي سابقاً '''BMS-477118''' وهو دواء فموي لمرض السكري من مثبطات DPP-4 | |||
<!-- | |||
'''Saxagliptin''' ([[International Nonproprietary Name|rINN]]), previously identified as '''BMS-477118''', is a new oral hypoglycemic ([[anti-diabetic drug]]) of the new [[DPP-4 inhibitors|dipeptidyl peptidase-4 (DPP-4) inhibitor]] class of drugs.<ref name="ahren">{{cite journal | author = Augeri D ''et al.'' | '''Saxagliptin''' ([[International Nonproprietary Name|rINN]]), previously identified as '''BMS-477118''', is a new oral hypoglycemic ([[anti-diabetic drug]]) of the new [[DPP-4 inhibitors|dipeptidyl peptidase-4 (DPP-4) inhibitor]] class of drugs.<ref name="ahren">{{cite journal | author = Augeri D ''et al.'' | ||
| title = Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | | title = Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | ||
| سطر 141: | سطر 142: | ||
*[http://www.forbes.com/2004/01/26/cx_mh_rl_diabetestearsheet_5.html The race to get DPP-4 inhibitors to market] - Forbes.com | *[http://www.forbes.com/2004/01/26/cx_mh_rl_diabetestearsheet_5.html The race to get DPP-4 inhibitors to market] - Forbes.com | ||
*{{cite web|url=http://www.medpagetoday.com/Washington-Watch/Washington-Watch/13555|title=Saxagliptin First Diabetes Drug to Pass FDA Cardiovascular Safety Review|last=Walker|first=Emily P.|work=}} | *{{cite web|url=http://www.medpagetoday.com/Washington-Watch/Washington-Watch/13555|title=Saxagliptin First Diabetes Drug to Pass FDA Cardiovascular Safety Review|last=Walker|first=Emily P.|work=}} | ||
--> | |||
{{بذرة}} | {{بذرة}} | ||
{{Oral hypoglycemics}} | {{Oral hypoglycemics}} | ||
مراجعة 10:23، 27 مارس 2013
| |
|---|---|
| Systematic (IUPAC) name | |
| (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile | |
| Clinical data | |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a610003 |
| Licence data | EMA:Link, US FDA:link |
| Pregnancy cat. | ? |
| Legal status | POM (UK) ℞-only (US) |
| Routes | Oral |
| Identifiers | |
| CAS number | 361442-04-8 
|
| ATC code | A10BH03 |
| PubChem | CID 11243969 |
| DrugBank | DB06335 |
| ChemSpider | 9419005 
|
| UNII | 8I7IO46IVQ
|
| ChEMBL | CHEMBL385517
|
| Chemical data | |
| Formula | C18H25N3O2 |
| Mol. mass | 315.41 g/mol |
| |
| |
 (what is this?) (verify) | |
الساكساغلبتين (بالإنجليزية: Saxagliptin) (rINN) سمي سابقاً BMS-477118 وهو دواء فموي لمرض السكري من مثبطات DPP-4
